Atrogi Ab

Boehringer Ingelheim International Gmbh

Oblique Therapeutics Ab

Biovitrum Ab

Astrazeneca Canada Inc.

Orexo Ab

Biolipox Ab

Abbott Laboratories Corporation

Karo Bio Ab

Astra Pharma Inc.

Benjamin Pelcman

Edgars Suna

Dirk Stenkamp

Henning Priepke

Roland Pfau

Raimund Kuelzer

Tore Bengtsson

Robert Roenn

Henri Doods

Edward Roberts

Dimitrijs Lubriks

William Stafford

Erik Ringberg

Jan Tejbrant

Markus Thor

Jonas Nilsson

Juergen Mack

Ivars Kalvins

Björn M Nilsson

Vita Ozola

Martins Katkevics

Mattias Jönsson

Martins Priede

Kristofer Olofsson

Philip R Kym

Kirsten Arndt

Owe Orwar

Klaus Klinder

Kjell Andersson

Bj&ouml;rn M Nilsson

Dace Katkevica

Annika Gustafsson

Mattias J&ouml;nsson

Peteris Trapencieris

Wesley Schaal

Vita Latvian Institute Of Organic Synthesis Ozola

Peteris Latvian Inst Of Organic Synthesis Trapencieris

Dace Latvian Inst Of Organic Synthesis Katkevica

Edgars Latvian Inst Of Organic Synthesis Suna

Martins Latvian Inst Of Organic Synthesis Katkevics

Ivars Latvian Inst Of Organic Synthesis Kalvins

There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, wherein the ring comprising Qto Q, R, m, Xand ring A have meanings as provided in the description.

Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia

There is herein provided a compound of formula (I).

Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Qto Q, and the groups R, Rand R, have meanings as provided in the description.

Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R, R, R, Rand n have meanings as provided in the description.

Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia

There is herein provided a compound of formula (I). 

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R, ring A, m and n have meanings as provided in the description. 

Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Qto Q, and the groups R, Rand R, have meanings as provided in the description. 

There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R, R, R, Rand n have meanings provided in the description, which compounds are useful in the treatment of cancers. 

Sulfinylpyridines and their use in the treatment of cancer

There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R, R, Rand X have meanings provided in the description, which compounds are useful in the treatment of cancers. 

Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer

Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer

Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer

This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R, R, R, R, R, Q, Q, Q, Z, Z, Z, Zand W have meanings given in the description.

Compounds

The present invention relates to compounds of general formula I in which A, L, M, Q, Q, Q, R, R, R, R, R, W, X, Y, Z, Z, Zare defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, R, Rhave meanings given in the description.

3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, Rhave meanings given in the description.

Inhibitors of the microsomal prostaglandin E2 synthase-1

Growing community of inventors

Stockholm, Sweden

Benjamin Pelcman